News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

IMPAX Laboratories, Inc. (IPXL) Confirms Patent Challenge Relating to Generic TOVIAZ® 4 Mg and 8 Mg


7/3/2013 8:33:12 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

HAYWARD, Calif.--(BUSINESS WIRE)--Impax Laboratories, Inc. (NASDAQ: IPXL) today confirms that it has initiated a challenge of the patents listed in the Orange Book in connection with TOVIAZĀ® (fesoterodine fumarate extended-release tablets, 4 mg and 8 mg).

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES